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Title: Should we use CT or MRI for detection and characterization of benign adrenal lesions? 
Abstract 
Objectives: Computed tomography (CT) and magnetic resonance imaging (MRI) are the main 
imaging modalities used for analysis of adrenal lesions. We compared the ability of CT and 
MRI to detect and characterize benign adrenal lesions. 
Material and methods: Unenhanced abdominal CT and MRI were performed in 16 patients 
(age range 39-77), and reviewed by a radiologist with 6 years of experience in abdominal 
imaging. The presence, number, size, and structure of each mass were analyzed and compared 
between the two modalities. 
Results: There were 18 adrenal masses in 11 patients, four patients had adrenal hyperplasia 
(AH), whereas one patient had left-sided AH and right-sided adenoma. Ten masses were ≥2 
cm in diameter, and were perfectly depicted using CT and all MRI techniques. There were 
nine masses with diameter <2 cm detected by CT, three of them were missed using MRI. AH 
was detected in five patients using CT, but its mild form was missed in one patient using 
MRI. Four masses with attenuation values of >10 Hounsfield units could not have been 
characterized using unenhanced CT, but three of them were characterized using MRI. 
Conclusion: CT has higher sensitivity for detection of small adrenal tumours and adrenal 
hyperplasia than MRI. MRI is an important tool in characterization of adrenal masses that 
could not be characterized using unenhanced CT. 
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Introduction 
Computed tomography (CT) and magnetic resonance imaging (MRI) are the main imaging 
modalities used for detection and characterization of adrenal lesions. Detection of small 
adrenal neoplasms is essential in patients with endocrine hypertension because most adrenal 
adenomas in patients with primary aldosteronism are smaller than 2 cm in diameter.
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Moreover, over 20% of hypersecreting tumours are less than 1 cm in diameter. On the other 
hand, characterization of adrenal pathology is very important, especially in patients with a 
known malignancy, because incidental adrenal nodules are present in approximately 5% of 
abdominal CT exams.
2,3
 
Despite of frequent use of CT and MRI in clinical practice, there are limited data in the 
literature showing which technique is more sensitive in detection of benign adrenal lesions, 
and which one should be preferred for their characterization. Moreover, most of the papers on 
this topic are concentrated on characterization of adenomas only,
4,5
 or were published before 
the era of contemporary multidetector CT and high magnetic field strength MRI scanners.
6,7
 
According to American College of Radiology (ACR) Appropriateness Criteria, CT and MRI 
are rated equally appropriate for the initial evaluation and follow-up of incidentally 
discovered adrenal masses >1 cm, but there are no data for determining the accuracy of 
imaging for masses measuring less than 1 cm.
8
 The decision to obtain CT or MRI is usually 
left to clinician preference and depends also on institutional experience.
9
 According to our 
experience, contrast-enhanced adrenal CT is a complex procedure that requires a radiologist 
available during the scanning, in order to immediately detect the mass, measure its 
attenuation, and decide whether contrast administration is needed. Therefore, our clinical 
experience with adrenal imaging in patients with endocrine hypertension is to start the 
evaluation using non-enhanced CT irrespective of patient’s age and renal function. Non-
enhanced is then followed by adrenal MRI if the lesion cannot be completely characterized 
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using non-enhanced CT. We also use MRI for further characterization of adrenal 
incidentalomas that are most frequently detected during CT examinations. In this study we 
compared the ability of these two modalities to detect and characterize benign adrenal lesions 
with special emphasis on small adrenal tumours (<2 cm).  
 
Material/Patients 
There were 16 patients (7 males and 9 females, age range 39-77) retrospectively included into 
the study. In all patients MRI examination of the adrenal glands was performed during one-
year period before the beginning of the study, and all patients had previous CT scan of 
adrenal glands available for comparison. Although arterial hypertension (blood pressure 
>140/80 mmHg) was present in 13 patients, suspicious secondary hypertension was indication 
for adrenal imaging in 9 patients only, whereas in all other hypertensive and non-hypertensive 
patients adrenal pathology was incidentally discovered during radiological workup of other 
diseases (Table 1). One hypertensive patient had biochemically proven primary 
aldosteronism, and the other previously underwent unilateral adrenalectomy because of 
pheochromocytoma. In one patient with previous colorectal and endometrial malignancy and 
incidentally discovered multiple adrenal masses, subclinical Cushing’s syndrome was 
detected after overnight dexamethasone suppression test. Hospital’s institutional review board 
approved the study, and informed consent was obtained from all patients. 
 
Methods/Imaging Protocols 
CT scanning was performed on a 40-detector row CT scanner (SOMATOM Sensation 40, 
Siemens Medical Solutions, Erlangen, Germany) without contrast administration, with 
collimation of 1.2 mm and breath-hold technique. 2-mm-thick slices were used for image 
analysis. The attenuation coefficient was measured within the lesions using circular region of 
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interest (ROI) as large as possible to include major part of the lesion and exclude surrounding 
structures. The mass was considered to be adrenocortical adenoma if it had attenuation values 
of -30 to +10 Hounsfield units (HU), whereas the mass was described to be myelolipoma if it 
had attenuation values of fat tissue (i.e. -150 to -31 HU). 
MRI examination was performed on a 1.5T scanner (MAGNETOM Avanto, Siemens Medical 
Solutions, Erlangen, Germany) using multichannel phased-array body coil. The scanning 
protocol included breath-hold nonenhanced axial gradient-recalled echo (GRE) T1 chemical-
shift imaging (TR 160 ms, TE 4.9/2.4 ms, slice thickness 4 mm, slice gap 20%, matrix 256), 
coronal GRE T1 chemical-shift imaging (TR 160 ms, TE 4.9/2.4 ms, slice thickness 3 mm, 
slice gap 10%, matrix 256), and axial three-dimensional (3D) volumetric interpolated breath-
hold examination (VIBE) fat-saturated T1-weighted sequence (TR 4.9 ms, TE 2.4 ms, slice 
thickness 3 mm, matrix 320). Furthermore respiratory triggered axial T2-weighted half-
Fourier acquisition single-shot turbo spin-echo (HASTE) images (TR 1350 ms, TE 91 ms, 
slice thickness 4 mm, slice gap 20%, matrix 256), and coronal T2 weighted HASTE images 
(TR 1350 ms, TE 91 ms, slice thickness 3 mm, slice gap 10%, matrix 256) were acquired. 
Circular ROI used to measure signal intensity (SI) within the lesion on chemical-shift MRI 
was as large as possible to cover the majority of the mass and not to include retroperitoneal 
fat tissue. Signal intensity index (SII) was calculated for all masses (SIIP SI on in-phase 
images, SIOP SI on out-of-phase images): 
SIIP
SIOPSIIP
SII
−
=  
The mass was characterized as adrenocortical adenoma if SII had value of >16.5%. The mass 
was classified as myelolipoma if it had high-signal of in-phase T1-weighted images with 
suppression of the signal on 3D VIBE T1-weighted fat-saturated images. 
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Data Analysis 
All CT and MRI exams were retrospectively reviewed by the same radiologist with 6 years of 
experience in abdominal imaging, who was blind on the clinical and hormonal data, as well 
on the results of the other imaging modality. The time interval between CT and MRI scanning 
ranged from 2 weeks to 57 months depending on the presence of extraadrenal malignancy and 
morphology of the adrenal mass. In all patients the morphology of adrenal glands has not 
been changed during this time interval. In all patients the presence, number, size, and 
structure of the mass were analyzed and compared between the two modalities. The final 
diagnosis was established based on CT and MRI findings, because none of the patients 
underwent adrenalectomy with pathohistological analysis of the adrenal glands. The patient 
with primary aldosteronism was treated conservatively with eplerenone because of high 
operative risk and good control of blood pressure and plasma potassium levels on 
conservative therapy. The patient with morphologically evident pheochromocytoma of the 
right adrenal gland has not undergone surgery because of previous left-sided adrenalectomy, 
and normal total urinary metanephrines. The patient with subclinical Cushing’s syndrome 
wasn’t treated surgically because adrenocortical adenomas were present bilaterally. 
 
Results 
There were 18 adrenal masses detected in 11 patients (10 adrenocortical adenomas, 5 
myelolipomas, 1 pheochromocytoma, 1 cyst, and 1 mass that remained uncharacterized), four 
patients had adrenal hyperplasia (3 unilateral and 1 bilateral), whereas one patient had left-
sided adrenal hyperplasia and adrenocortical adenoma of the right adrenal gland. 
Ten masses were ≥2 cm in diameter (8 adrenocortical adenomas, a pheochromocytoma and a 
cyst), and were perfectly depicted using CT and all MRI techniques. There were 9 masses 
with diameter <2 cm (3 adrenocortical adenomas, 5 myelolipomas and one uncharacterized 
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mass), three of them were smaller than 1 cm in diameter (one adenoma, two myelolipomas). 
All masses with diameter <2 cm were detected using CT. Three masses with diameter <2 cm 
were missed using MRI: one right-sided adrenocortical adenoma, and 2 left-sided 
myelolipomas. This right-sided adrenocortical adenoma was located in proximity to the right 
hepatic lobe and inferior caval vein, and was overlooked because of poorer spatial resolution 
of MRI compared to CT. One myelolipoma with diameter <1 cm was missed due to 
insufficient spatial resolution of MRI and looked as incisure within the adrenal gland 
parenchyma (Fig. 1), whereas the other was located extraadrenally and could not be 
differentiated from the retroperitoneal adipose tissue using MRI. 
Four masses with attenuation values of >10 HU could not be characterized using unenhanced 
CT (two masses in patients with known malignancy, one in a patient with previously resected 
pheochromocytoma, and one in a patient with incidentally discovered adrenal mass during 
health check-up ultrasonography). Three of these masses were characterized using MRI as an 
adrenal cyst (Fig. 2), pheochromocytoma (Fig. 3), and adrenocortical adenoma (Fig. 4). In a 
patient with a mass described as pheochromocytoma, there was no biochemical evidence of 
pheochromocytoma and the patient has not undergone surgery. One mass with diameter <2 
cm in a patient with previous colorectal and endometrial cancer couldn’t be characterized 
using any of the techniques (Fig. 5), but remained unchanged during 14 months and was 
therefore considered to be benign. One mass with attenuation values of -30 HU was 
incorrectly characterized as adrenocortical adenoma using non-enhanced CT, whereas on MRI 
it was evident that it was myelolipoma, composed mostly of adipose tissue that lost its signal 
after fat suppression (Fig. 6). 
Adrenal hyperplasia was detected in five patients, and it was bilateral in one patient only. 
Two patients had more extensive form of hyperplasia with crural thickness of >1 cm. In these 
two patients and in two patients with unilateral mild form of adrenal hyperplasia, it was 
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detected using both CT and MRI. Adrenal hyperplasia was easily detected using CT, whereas 
in all patients out-of-phase GRE technique was the best MRI sequence to depict adrenal 
hyperplasia because hypertrophic adrenal gland was surrounded by india ink artifact (Fig. 7). 
In one patient with contralateral adrenocortical adenoma, the mild form of unilateral adrenal 
hyperplasia was detected using CT, but was missed using MRI due to lower spatial resolution. 
 
Discussion 
Depiction of discrete adrenal changes is of utmost importance in patients with endocrine 
hypertension because it is frequently caused by hormone hypersecretion within small adrenal 
tumours. Using imaging techniques it may be difficult to accurately identify and measure the 
adrenal glands and distinguish them from normal adjacent structures.
10
 According to the 
results of our study, CT has better sensitivity for detection of small adrenal tumours than MRI 
that missed 3 out of 9 small tumours detected using CT. The main explanation for the greater 
sensitivity of CT is the better spatial resolution, smaller slice thickness and paucity of 
respiratory artifacts on CT compared to MRI. CT is fast and readily available technique with 
lower cost than MRI, and can detect adrenal masses >5 mm in diameter.
11
 Therefore, we 
believe that CT should be preferred method for detection of adrenal pathology in patients with 
clinical and laboratory findings of an adrenal endocrinopathy, because it is frequently caused 
by a lesion <2 cm in size. In such patients MRI could be used for follow-up, especially in 
younger patients, in order to prevent unnecessary use of ionizing radiation, and to characterize 
the tumour if the characterization was not possible using CT. 
In our study, only one out of 19 tumours could not have been characterized using MRI, 
compared to 4 out of 19 tumours that were not characterized using unenhanced CT. 
Furthermore, one mass was incorrectly characterized based measurement of attenuation 
values on unenhanced CT. Characterization of adrenal masses is especially important in 
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patients with a known malignancy, because adrenal gland is the frequent site of metastatic 
disease that presents up to 36 percent of incidentally discovered adrenal tumours in patients 
with known malignancy.
12
 Adrenal metastases should be morphologically differentiated from 
non-functioning adrenal adenomas that are incidentally discovered in up to 5% of abdominal 
CT examinations in adult patients without malignancy,
2,3
 and even more often in patients with 
a known malignancy.
13
 In patients with a primary extraadrenal neoplasm and no other 
evidence of distant metastatic disease, characterization of the lesion using noninvasive 
imaging can reduce the necessity for percutaneous adrenal mass biopsy in most patients.
14
 
Characterization of lipid-rich adenomas is straightforward using both unenhanced CT and 
MRI, and represented with attenuation values of ≤10 HU on CT, and obvious signal drop on 
opposed-phase MRI.
13
 Unfortunately, about 29% of adenomas have attenuation values higher 
than 10 HU and remain indeterminate on unenhanced CT scan.
15
 They could be distinguished 
from other pathology on contrast-enhanced CT with quantification of contrast material 
washout, but the radiologist should be available during examination in order to decide 
whether additional contrast-enhanced scanning is needed. For washout calculation, the 
scanning protocol requires at least dual-phase acquisition (i.e. venous and delayed phase), 
which is usually not performed in patients with malignancies and other extraadrenal 
pathology. That could lead to insufficient characterization of the mass on CT, even after 
contrast administration. Furthermore, intravenous contrast administration should be avoided 
in patients with renal insufficiency and allergy to contrast media, which makes the washout 
calculation impossible. For quantification of relative washout dual-phase acquisition is 
sufficient, while for calculation of absolute washout, unenhanced, venous and delayed phase 
should be scanned, leading to high radiation dose. Moreover, the assessment of enhancement 
washout of adrenal masses is valid only for lesions with relatively homogeneous attenuation 
after contrast administration.
14
 To avoid unnecessary use of ionizing radiation, especially in 
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younger patients, adrenal MRI could be of great help in characterization of adrenal masses. 
Depiction of calcifications within the tumour is not possible using MRI, but calcifications are 
not typical for benign adrenal masses and visualization of calcification doesn’t help much in 
adrenal mass characterization in adults. 
We showed that MRI has very good soft-tissue resolution that allowed correct 
characterization of an adrenal cyst. Lipid-rich adrenal adenomas and cysts have similar 
attenuation to water, and a cyst can be misinterpreted as an adenoma on non-enhanced CT. To 
differentiate adrenal cysts from adenomas using CT, contrast material should be administered 
in order to show its lack of enhancement.
16
 In our patient the cyst could not have been 
characterized using non-enhanced CT because of dense intracystic content with attenuation 
values of 20 HU. On MRI this mass had homogeneous low T1 and high T2 signal, 
characteristic of a cyst, contained a thin rim, and did not lose signal on chemical-shift imaging 
(Fig. 2). 
In the other patient with previously resected huge pheochromocytoma of the left adrenal 
gland, we found the heterogeneous right adrenal mass with high signal intensity on T2-
weighted MRI examination (Fig. 3), that has been described as a typical characteristic of 
pheochromocytoma.
17,18
 The mass of the right adrenal gland had diameter of 2,2 cm, and was 
unchanged compared to preoperative imaging. The diagnosis of pheochromocytoma was not 
confirmed biochemically probably because of the size of the tumour, and the patient has not 
been operated. However, the diagnosis of pheochromocytoma could not have been excluded 
since 7% of pheochromocytoma patients have normal 24-hour urinary fractionated 
catecholamines, and 7% have normal total urinary metanephrines.
19
 
Furthermore, using chemical-shift GRE imaging, we managed to depict intracellular lipids 
within a mass with density of 31 HU on unenhanced CT scan, confirming that it was 
adrenocortical adenoma (Fig. 4). The loss of SI on out-of-phase images was visually obvious, 
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and SII was calculated to be 67%. MRI can identify a small group of lipid-poor adenomas 
with the density of >10 HU on unenhanced CT, but with sufficient lipid content to be detected 
using chemical-shift GRE imaging [11]. The sensitivity of chemical-shift MRI for adenoma is 
89% for masses with attenuation coefficient of 10-30 HU, and 75% for adenomas with 
attenuation of 20-30 HU.
20
 Quantitative approach with calculation of SII allows their correct 
characterization, obviating the need for contrast administration. Therefore, chemical-shift 
MRI should be the second-line imaging tool for characterization of hyperattenuating adrenal 
masses. 
MRI was also helpful in correct characterization of a myelolipoma. The presence of gross fat 
on CT with density of less than 30 HU is diagnostic of myelolipoma.
18
 One mass in our study 
had density of −30 HU and on CT it was described as a lipid-rich adenoma (Fig. 6). In this 
patient the mass had high signal on T1 weighted images, with obvious fat-suppression on 3D 
VIBE MRI technique, confirming that the lesion consisted of macroscopic fat tissue and that 
the mass was myelolipoma. 
Adrenal hyperplasia can also be the cause of hormone hypersecretion leading to secondary 
hypertension. The normal adrenal body measures less than 10-12 mm, and the adrenal limbs 
normally measure less than 5-6 mm.
18
 In hyperplasia the adrenals are usually enlarged 
bilaterally, and maintain an adreniform shape with smooth surface, less often they are 
nodularly enlarged. In our study, its mild form was missed in one out of five patients on MRI, 
due to lower spatial resolution compared to CT. This further confirms our hypothesis that CT 
should be the first imaging modality for detection of adrenal pathology in patients with 
endocrine hypertension. If MRI is used for follow-up, out-of-phase chemical shift imaging 
allows better depiction of adrenal hyperplasia than in-phase and T2 weighted images, because 
the enlarged adrenal gland is surrounded by india ink artifact. 
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Although lesions with diameter <1 cm are usually considered to be too small to be 
characterized,
21
 we managed to characterize all three tumours that were smaller than 1 cm. 
Two masses with diameter <1 cm were myelolipomas, that could easily be differentiated from 
the adrenal gland due to very different density and signal intensity. The third mass was small 
lipid-rich adenoma of the right adrenal gland in a patient with abundant retroperitoneal fat 
tissue. However, although small adrenal tumours can easily be misinterpreted due to partial 
volume effects,
21
 in some instances they can be detected and characterized using imaging 
techniques. With technical improvement of the scanners, it can be expected that we would be 
able to detect and characterize more masses with diameter <1 cm, even in slim patients. 
The main limitation of our investigation is the low number of patients and lesions included in 
the study. The lesions were of different size and aetiology, and were not confirmed 
histologically. Therefore, we believe that these very indicative results of our investigation 
should be confirmed in a larger group of patients. 
 
Conclusion 
We believe that in clinical practice unenhanced CT should be the first-line modality for 
adrenal imaging in patients with endocrine hypertension, since it is readily available, rapidly 
performed, and has good sensitivity for detecting adrenal lesions. For lesions that remain 
indeterminate on unenhanced CT, the lesion should be characterized using MRI. 
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Table 1 Demographic, clinical and radiological data of patients included in the study. 
Patient 
No 
Age 
(years) 
Gender 
Arterial 
hypertension 
Indication 
for imaging 
Hormone 
analysis 
Interval 
between 
CT and MRI 
(months) 
Final diagnosis CT findings MRI findings 
1 77 M no urolithiasis normal 11 adenoma (≥2 cm) 
lipid-rich 
adenoma 
lipid-rich 
adenoma 
2 51 F yes 
arterial 
hypertension 
normal 6 adenoma (≥2 cm) 
lipid-rich 
adenoma 
lipid-rich 
adenoma 
3 54 F yes abdominal pain normal 6 adenoma (≥2 cm) 
lipid-rich 
adenoma 
lipid-rich 
adenoma 
4 69 M yes 
arterial 
hypertension 
primary 
hyperaldo-
steronism 
36 
right-sided adenoma (≥2 
cm), left-sided adrenal 
hyperplasia (<1 cm) 
lipid-rich 
adenoma, 
adrenal 
hyperplasia 
lipid-rich 
adenoma 
5 65 F yes 
arterial 
hypertension 
normal 18 
bilateral adrenal adenomas 
(one <2 cm and one ≥2 
cm) 
bilateral lipid-
rich adenomas 
bilateral lipid-
rich adenomas 
6 61 M no 
staging of urinary 
bladder cancer 
normal 0.5 
unilateral adrenal 
hyperplasia (>1 cm) 
adrenal 
hyperplasia 
adrenal 
hyperplasia 
7 52 F yes 
arterial 
hypertension 
normal 16 
unilateral adrenal 
hyperplasia (<1 cm) 
adrenal 
hyperplasia 
adrenal 
hyperplasia 
8 39 F yes 
previously operated 
pheochromo-
cytoma 
normal 12 
pheochromocytoma (≥2 
cm) 
uncharacterized 
mass  
(attenuation 20 
HU) with 
calcification 
heterogeneous 
mass with high 
signal on T2wI 
9 54 F yes 
arterial 
hypertension 
normal 8 adenoma (≥2 cm) 
lipid-rich 
adenoma 
lipid-rich 
adenoma 
10 57 M yes 
arterial 
hypertension 
normal 27 
bilateral adrenal 
hyperplasia (>1 cm) 
bilateral adrenal 
hyperplasia 
bilateral adrenal 
hyperplasia 
11 44 M no 
ultrasonogra-
phically detected 
mass (health 
checkup) 
normal 5 adenoma (<2 cm) 
uncharacterized 
mass 
(attenuation 31 
HU) 
lipid-rich 
adenoma 
16 
 
12 57 F yes 
arterial 
hypertension 
normal 30 
unilateral adrenal 
hyperplasia (<1 cm) 
adrenal 
hyperplasia 
adrenal 
hyperplasia 
13 67 M yes 
arterial 
hypertension 
normal 57 
adrenal myelolipoma (<2 
cm) 
lipid-rich 
adenoma 
adrenal 
myelolipoma 
14 66 M yes liver lesion normal 27 
4 adrenal myelolipomas 
(<2 cm) 
4 adrenal 
myelolipomas 
2 adrenal 
myelolipomas 
15 58 F yes 
colorectal and 
endometrial cancer 
follow-up 
subclinical 
Cushing's 
syndrome 
14 
3 adenomas (one <2 cm 
and two ≥2 cm), one 
uncharacterized mass (<2 
cm) 
3 lipid-rich 
adenomas, one 
uncharacterized 
mass 
(attenuation 27 
HU) 
2 lipid-rich 
adenomas, one 
uncharacterized 
mass 
16 65 F yes 
renal-cell 
carcinoma follow-
up 
adrenal 
cyst 
5 adrenal cyst (≥2 cm) 
uncharacterized 
mass 
(attenuation 20 
HU) 
adrenal cyst 
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Figure Captions 
Fig. 1 66-year-old men with diffuse liver lesion. Small myelolipoma (arrow) of left adrenal 
gland on CT (a), that looked as an incisure within the adrenal gland parenchyma on MRI (b, 
axial gradient-echo fat-saturated T1-weighted image) 
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Fig. 2 65-year-old female referred for follow-up of renal cancer. A mass (arrow) of the right 
adrenal gland with attenuation value of 20 Hounsfield units could not have been characterized 
using unenhanced CT (a). It was characterized using T2-weighted MRI as an adrenal cyst (b) 
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Fig. 3 39-year-old woman with residual arterial hypertension after left-sided adrenalectomy 
due to pheochromocytoma. The right adrenal mass (arrow) had attenuation value of 20 HU on 
non-enhanced CT with a punctiform calcification (a), whereas it had typical high-signal 
intensity of pheochromocytoma on T2-weighted MRI (b) 
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Fig. 4 44-year-old male with left-adrenal mass detected on check-up ultrasonography. Small 
left-sided adrenal adenoma (arrow) with attenuation of 31 Hounsfield units could not be 
characterized on non-enhanced CT (a), whereas it had obvious signal drop on out-of-phase 
MRI (b) compared to in-phase MRI (c) with signal-intensity-index of 67% 
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Fig. 5 58-year-old female referred for follow-up of colorectal and endometrial cancer. The 
left-sided adrenal mass (arrow) remained uncharacterized after CT (a) and MRI (b, out-of-
phase chemical-shift MRI). It remained unchanged after 14 months and was therefore 
considered to be benign. Typical lipid-rich adenoma of the right adrenal gland (asterisk) 
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Fig. 6 67-year-old men with arterial hypertension and myelolipoma of the left adrenal-gland 
(arrow). On non-enhanced CT (a) the mass had attenuation coefficient of -30 Hounsfield 
units, and was therefore interpreted as adenoma. On MRI signal loss on gradient-echo fat-
saturated T1-weighted image was obvious (b) 
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Fig. 7 61-year-old male referred for follow-up urinary bladder cancer. Adrenal hyperplasia 
(arrow) was easily detected using CT (a), and out-of-phase gradient-echo MRI sequence 
where hypertrophic adrenal gland was surrounded by india ink artifact (b) 
 
   
